Open AccessOutcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis
Author(s) -
Alessandro Randazzo,
Raffaele Raimondi,
Giovanni Fossati,
Mercedes Romano,
Tania Sorrentino,
Carlo Castellani,
Costanza Rossi,
Giuseppe Cancian,
Paolo Vinciguerra
Publication year - 2021
Publication title -
journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 40
eISSN - 2090-0058
pISSN - 2090-004X
DOI - 10.1155/2021/7940297
Subject(s) - medicine , aflibercept , macular degeneration , bevacizumab , center (category theory) , retrospective cohort study , ophthalmology , surgery , chemotherapy , chemistry , crystallography
Purpose To assess real-life anatomical and functional outcomes of switch to bevacizumab in patients undergoing aflibercept intravitreal injections for nAMD.Methods Retrospective chart review of all patients diagnosed with nAMD and undergoing intravitreal injections of aflibercept who switched to bevacizumab after the resolution XI/1986 of Lombardy Region.Results Among 128 patients undergoing intravitreal injections, a total of 29 eyes of 29 patients met all inclusion criteria and were included in the statistical analysis. Best corrected visual acuity and central macular thickness did not change significantly ( p > 0.05) between baseline, after the loading phase, and at the last follow-up.Conclusion Switching to bevacizumab has been safe and efficacious in patients responding to the loading phase. According to our results, the restrictions imposed by Lombardy Region did not cause any harm to patients undergoing intravitreal anti-VEGF injections.